Gene Expression Studies in Leiomyomata: New Directions for Research

William Catherino; Amal Salama; Clariss Potlog-Nahari; Phyllis Leppert; John Tsibris; James Segars

doi:10.1055/s-2004-828614

Seminars in Reproductive Medicine, Table of Contents

Semin Reprod Med 2004; 22(2): 83-90
DOI: 10.1055/s-2004-828614

Published 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Gene Expression Studies in Leiomyomata: New Directions for Research

William Catherino¹ , Amal Salama¹ , Clariss Potlog-Nahari¹ , Phyllis Leppert¹ , John Tsibris² , James Segars¹

¹Pediatric and Reproductive Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, and Department of Obstetrics and Gynecology, Uniformed Services University of the Health Sciences, Bethesda, Maryland
²Department of Obstetrics and Gynecology, University of South Florida, Tampa, Florida

Abstract

Uterine leiomyomata (fibroids) are a leading women's health problem, resulting in significant morbidity and surgical intervention. As benign clonal tumors, leiomyomata also represent a target well suited to molecular analysis. Familial studies and genetic syndromes featuring leiomyomata provide compelling evidence that genetic alterations may cause fibroid development, but the specific genes involved in leiomyoma development have not been identified. Microarrays permit simultaneous comparison of the relative expression of thousands of genes, thereby highlighting specific genes that may play a role in the development of leiomyomata. Microarray studies conducted by several laboratories have identified candidate genes. However, few gene products have been confirmed with alternative experimental approaches. The objective of this article is to focus on the insights provided by microarray studies investigating leiomyoma development. Such studies suggest that although hormonal control of leiomyoma growth is observed, there are other critical pathways involved in development of the leiomyoma cell phenotype that warrant investigation. In particular, expression of extracellular matrix genes in leiomyomata is deranged and such genes represent potential novel targets for therapy.

KEYWORDS

Leiomyomata - microarray - extracellular matrix - molecular genetics - fibroids

Full Text

References

REFERENCES

1 Stewart E A. Uterine fibroids. Lancet. 2001; 357 293-298
2 Gross K L, Morton C C. Genetics and the development of fibroids. Clin Obstet Gynecol. 2001; 44 335-349
3 Myers E R, Barber M D, Gustilo-Ashby T, Couchman G, Matchar D B, McCroy D C. Management of uterine leiomyomata: what do we really know?. Obstet Gynecol. 2002; 100 8-17
4 Forster T, Roy D, Ghazal P. Experiments using microarray technology: limitations and standard operating procedures. J Endocrinol. 2003; 178 195-204
5 Tsibris J C, Segars J, Coppola D et al.. Insights from gene arrays on the development and growth regulation of uterine leiomyomata. Fertil Steril. 2002; 78 1-8
6 Tsibris J CM, Maas S, Segars J et al.. New potential regulators of uterine leiomyomata from DNA arrays: the ionotropic glutamate receptor GluR2. Biochem Biophys Res Commun. 2003; 312 249-254
7 Skubitz K, Skubitz A. Differential gene expression in uterine leiomyoma. J Lab Clin Med. 2003; 141 297-308
8 Catherino W, Prupas C, Tsibris J et al.. Strategy for elucidating differentially expressed genes in leiomyoma identified by microarry technology. Fertil Steril. 2003; 80 282-290
9 Catherino W H, Leppert P C, Stenmark M et al.. Reduced dermatopontin expression is a molecular link between uterine leiomyomata and keloids. Genes Chromosomes Cancer.. , In press
10 Chegini N, Verala J, Luo X, Xu J, Williams R. Gene expression profile of leiomyoma and myometrium and the effect of gonadotropin releasing hormone analogue therapy. J Soc Gynecol Investig. 2003; 10 161-171
11 Wang H, Mahadevappa M, Yamamoto K et al.. Distinctive proliferative phase differences in gene expression in human myometrium and leiomyomata. Fertil Steril. 2003; 80 266-276
12 Christman G M, McCarthy J D. Gene therapy and uterine leiomyomas. Clin Obstet Gynecol. 2001; 44 425-435
13 Spitz I M, Chwalisz K. Progesterone receptor modulators and progesterone antagonists in women's health. Steroids. 2000; 65 807-815
14 Nowak R. Novel therapeutic strategies for leiomyomas: targeting growth factors and their receptors. Environ Health Perspect. 2000; 108 849-853
15 Ligon A, Morton C. Leiomyomata: heritability and cytogenetic studies. Hum Reprod Update. 2001; 7 8-14
16 Sato F, Mori M, Nishi M, Kudo R, Miyake H. Familial aggregation of uterine myomas in Japanese women. J Epidemiol. 2002; 12 249-253
17 Marshall L, Spiegelman D, Barbieri R et al.. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol. 1997; 90 967-973
18 Kashtan C E. Alport syndrome. An inherited disorder of renal, ocular, and cochlear basement membranes. Medicine (Baltimore). 1999; 78 338-360
19 Sampson N S, Ryan S T, Enke D A, Cosgrove D, Koteliansky V, Gotwals P. Global gene expression analysis reveals a role for the α₁ integrin in renal pathogenesis. J Biol Chem. 2001; 276 34182-34188
20 Reed W B, Walker R, Horowitz R. Cutaneous leiomyomata with uterine leiomyomata. Acta Derm Venereol. 1973; 53 409-416
21 Martinez-Mir A, Gordon D, Horev L et al.. Multiple cutaneous and uterine leiomyomas: refinement of the genetic locus for multiple cutaneous and uterine leiomyomas on chromosome 1q42.3-43. J Invest Dermatol. 2002; 118 876-880
22 Mitelman F, Mertens F, Johansson B. A breakpoint map of recurrent chromosomal rearrangements in human neoplasia. Nat Genet. 1997; 15 417-474
23 Dal Cin P, Quade B J, Neskey D M, Kleinman M S, Weremowicz S, Morton C. Intravenous leiomyomatosis is characterized by a der(14)t(12;14)(q15;q24). Genes Chromosomes Cancer. 2003; 36 205-206
24 Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors. Ann Chir Gynaecol. 1998; 87 278-281
25 Venter J C, Adams M D, Myers E W et al.. The sequence of the human genome. Science. 2001; 291 1304-1351
26 Freije W A. Genome biology and gynecology: the application of oligonucleotide microarrays to leiomyomata. Fertil Steril. 2003; 80 277-278
27 Walker C L. Role of hormonal and reproductive factors in the etiology and treatment of uterine leiomyoma. Recent Prog Horm Res. 2002; 57 277-294
28 Tsibris J C, Porter K B, Jazayeri A et al.. Human uterine leiomyomata express higher levels of peroxisome proliferator-activated receptor γ, retinoid X receptor α, and all-trans retinoic acid than myometrium. Cancer Res. 1999; 59 5737-5744
29 Houston K D, Copland J A, Broaddus R R, Gottardis M M, Fischer S M, Walker C L. Inhibition of proliferation and estrogen receptor signaling by peroxisome proliferators-activated receptor γ ligands in uterine leiomyoma. Cancer Res. 2003; 63 1221-1227
30 Nelson K G, Takahashi T, Bossert N L, Walmer D K, McLachlan J A. Epidermal growth factor replaces estrogen in the stimulation of female genital-tract growth and differentiation. Proc Natl Acad Sci U S A. 1991; 88 21-25
31 Kalir T, Goldstein M, Dottino P et al.. Morphometric and electron-microscopic analyses of the effects of gonadotropin-releasing hormone agonists on uterine leiomyomas. Arch Pathol Lab Med. 1998; 122 442-446
32 Kresse H, Schönherr E. Proteoglycans of the extracellular matrix and growth control. J Cell Physiol. 2001; 189 266-274
33 Iozzo R. The biology of small leucine-rich proteoglycans. Functional network of interactive proteins. J Biol Chem. 1999; 274 18843-18846
34 Yamaguchi Y. Lecticans: organizers of the brain extracellular matrix. Cell Mol Life Sci. 2000; 57 276-289
35 Melrose J, Ghosh P, Taylor T. A comparative analysis of the differential spatial and temporal distributions of the large (aggrecan, versican) and small (decorin, biglycan, fibromodulin) proteoglycans of the intervertebral disc. J Anat. 2001; 198 3-15
36 Soriano E S, Campos M, Michelacci Y M. Effect of epithelial debridement on glycosaminoglycan synthesis by human corneal explants. Clin Chim Acta. 2000; 295 41-62
37 Berto A, Sampaio L, Franco C, Cesar Jr R, Michelacci Y. A comparative analysis of structure and spatial distribution of decorin in human leiomyoma and normal myometrium. Biochim Biophys Acta. 2003; 1619 98-112
38 Mehra A, Wrana J L. TGF-beta and the Smad signal transduction pathway. Biochem Cell Biol. 2002; 80 605-622
39 Massague J, Wotton D. Transcriptional control by the TGF-β/Smad signaling system. EMBO J. 2000; 19 1745-1754
40 Border W A, Noble N A. Transforming growth factor in tissue fibrosis. N Engl J Med. 1994; 331 1286-1292
41 Lee B S, Nowak R A. Human leiomyoma smooth muscle cells show increased expression of transforming growth factor-beta 3 (TGF beta 3) and altered responses to the antiproliferative effects of TGF beta. J Clin Endocrinol Metab. 2001; 86 913-920
42 Nowak R. Identification of new therapies for leiomyomas: what in vitro studies can tell us. Clin Obstet Gynecol. 2001; 44 327-333
43 Arici A, Sozen I. Transforming growth factor-β3 is expressed at high levels in leiomyoma where it stimulates fibronectin expression and cell proliferation. Fertil Steril. 2000; 73 1006-1011
44 Xu J, Luo X, Chegini N. Differential expression, regulation, and induction of smads, transforming growth factor-β signal transduction pathway in leiomyoma, and myometrial smooth muscle cells and alteration by gonadotropin-releasing hormone analog. J Clin Endocrinol Metab. 2003; 88 1350-1361
45 Moustakas A, Souchelnytskyi S, Heldin C H. Smad regulation in TGF-β signal transduction. J Cell Sci. 2001; 114 4359-4369
46 Fukuhara K, Kariya M, Kita M et al.. Secreted frizzled related protein 1 is overexpressed in uterine leiomyomas, associated with a high estrogenic environment and unrelated to proliferative activity. J Clin Endocrinol Metab. 2002; 87 1729-1736
47 Wong L L, Adler P N. Tissue polarity genes of Drosophila regulate the subcellular location for prehair pupal wing cells. J Cell Biol. 1993; 123 209-221
48 Nakamura T, Sano M, Songyang Z, Schneider M D. A Wnt- and β-catenin-dependent pathway for mammalian cardiac myogenesis. Proc Natl Acad Sci U S A. 2003; 100 5834-5839
49 Figarella-Branger D, Moreau H, Pellissier J F, Bianco N, Rougon G. CD24, a signal-transducing molecule expressed on human B lymphocytes, is a marker for human regenerating muscle. Acta Neuropathol (Berl). 1993; 86 275-284
50 Kay R, Rosten P M, Humphries R K. CD24, a signal transducer modulating B cell activation responses, is a very short peptide with a glycosyl phosphatidylinositol membrane anchor. J Immunol. 1991; 147 1412-1416
51 Rougon G, Alterman L A, Dennis K, Guo X-J, Kinnon C. The murine heat-stable antigen: a differentiation antigen expressed in both the hematolymphoid and neural cell lineages. Eur J Immunol. 1991; 21 1397-1402
52 Jackson D, Waibel R, Weber E, Bell J, Stahel R A. CD24, a signal-transducing molecule expressed on human B cells, is a major surface antigen on small cell lung carcinomas. Cancer Res. 1992; 52 5264-5270
53 Walocha J A, Litwin J A, Miodonski A J. Vascular system of intramural leiomyomata revealed by corrosion casting and scanning electron microscopy. Hum Reprod. 2003; 18 1088-1093
54 Gill S S, Pulido O M. Glutamate receptors in peripheral tissues: current knowledge, future research, and implications for toxicology. Toxicol Pathol. 2001; 29 208-223

James SegarsM.D.

Building 10, Room 9D-42, PREB, NICHD, NIH, 9000 Rockville Pike

Bethesda, MD 20862